Emma Walmsley and her GSK CEO successor, Luke Miels, are safeguarding the British pharma’s 40-billion-pound sales projection ...

GlaxoSmithKline‘s (NYSE:GSK) efforts to clear its figurative medicine cabinet of unwanted over-the-counter products continues as the pharma giant reaches a deal to sell a group of consumer brands to ...

GlaxoSmithKline (NYSE:GSK) dermatology and skin subsidiary Stiefel has submitted to regulators a new drug application for tazarotene foam, an acne skin care treatment product. If approved by the U.S.

GlaxoSmithKline ( ($GB:GSK) ) has shared an announcement. GSK has announced the purchase of 175,000 of its own ordinary shares as part of its ...

Prefilled syringe offers a convenient ready-to-use administration option to healthcare professionals·        Marketing authorisation in EU expected in December ...

GSK acquires exclusive rights from Syndivia for an ADC targeting advanced prostate cancer in a deal up to £268 m, reinforcing ...

LONDON/MUMBAI (Reuters) - Indian generics firm Lupin , some U.S. drugmakers looking for a tax-saving deal in Europe and private equity funds are planning to bid for a range of older drugs being ...

Prestige said the GlaxoSmithKline brands will start adding to its profit in the fiscal year starting April 1. It said over-the-counter products will account for about 85 percent of revenue, or about ...

(Reuters) - Private equity firms are mulling over a $10 billion plan to buy and merge older drug brands of Britain's GlaxoSmithKline and France's Sanofi , the Financial Times reported on Sunday, ...